Radiation Medicine Program, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada.
Acta Oncol. 2009;48(7):1034-43. doi: 10.1080/02841860903099972.
To evaluate diffusion weighted magnetic resonance imaging (DWI) in liver and liver cancers during and following conformal radiotherapy (RT). To determine the feasibility of using changes in apparent diffusion coefficients (ADC) as a potential surrogate for tumour control or normal tissue injury.
Patients on a six-fraction conformal liver RT protocol underwent DW-MRI at the time of treatment planning, during RT (week one and two) and one month following RT. Diffusion weighted MR images were acquired in exhale breath hold, using b-values of 0 and 600. Regions of interest (ROIs) corresponding to maximal tumour dose, high-dose peri-tumour liver, irradiated normal liver, non-irradiated liver, and spleen were analyzed on ADC maps.
Eleven patients (four hepatocellular carcinoma, five liver metastases, two cholangiocarcinoma) were evaluated. The baseline median tumour ADC of 1.56 x 10(-3)mm(2)/sec increased to 1.89 x 10(-3)mm(2)/sec at RT week one, to 1.91 x 10(-3)mm(2)/sec during week two and to 2.01 x 10(-3)mm(2)/sec at one month following treatment (p < 0.0001). Early increases in mean ADC were correlated with higher dose and sustained tumour response, whereas RECIST and volume changes on T2 images were not. Peri-tumour mean ADC also increased, from 1.40 x 10(-3)mm(2)/sec (baseline) to 1.55 x 10(-3)mm(2)/sec (RT week 2) and 1.64 x 10(-3)mm(2)/sec (follow-up). Small ADC changes were seen in the irradiated liver, and no significant changes were seen in the un-irradiated liver.
Changes in tumour ADC were seen during RT. Larger increases were correlated with higher doses and increased likelihood of response.
评估扩散加权磁共振成像(DWI)在肝和肝癌中的作用,包括在适形放疗(RT)期间和之后的作用。确定表观扩散系数(ADC)变化是否可作为肿瘤控制或正常组织损伤的潜在替代指标。
在接受六部分适形肝 RT 方案的患者中,在治疗计划时、RT 期间(第 1 周和第 2 周)以及 RT 后 1 个月进行 DWI-MRI。在呼气屏气时使用 b 值为 0 和 600 采集扩散加权 MR 图像。在 ADC 图上分析与最大肿瘤剂量、高剂量肿瘤周围肝、受照正常肝、未受照肝和脾脏相对应的感兴趣区(ROI)。
共评估了 11 例患者(4 例肝细胞癌、5 例肝转移瘤、2 例胆管癌)。基线时肿瘤 ADC 的中位数为 1.56×10(-3)mm(2)/sec,第 1 周 RT 时增加到 1.89×10(-3)mm(2)/sec,第 2 周时增加到 1.91×10(-3)mm(2)/sec,在治疗后 1 个月时增加到 2.01×10(-3)mm(2)/sec(p<0.0001)。早期平均 ADC 增加与更高剂量和持续肿瘤反应相关,而 RECIST 和 T2 图像上的体积变化则没有。肿瘤周围平均 ADC 也增加,从 1.40×10(-3)mm(2)/sec(基线)增加到 1.55×10(-3)mm(2)/sec(第 2 周 RT)和 1.64×10(-3)mm(2)/sec(随访)。受照肝中可见 ADC 变化较小,未受照肝中未见明显变化。
在 RT 期间可见肿瘤 ADC 变化。更大的增加与更高的剂量和增加的反应可能性相关。